These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 11575179

  • 1. [How well do gyrase inhibitors work? The pharmacokinetics of quinolones].
    Sörgel F, Bulitta J, Kinzig-Schippers M.
    Pharm Unserer Zeit; 2001; 30(5):418-27. PubMed ID: 11575179
    [No Abstract] [Full Text] [Related]

  • 2. [How are quinolones used in clinical practice? Gyrase antagonists from the viewpoint of the hospital pharmacist].
    Schurz JK.
    Pharm Unserer Zeit; 2001; 30(5):400-5. PubMed ID: 11575176
    [No Abstract] [Full Text] [Related]

  • 3. [Quinolones in the environment: biological breakdown of gyrase inhibitors].
    Wetzstein HG.
    Pharm Unserer Zeit; 2001; 30(5):450-7. PubMed ID: 11575183
    [No Abstract] [Full Text] [Related]

  • 4. [Quinolones. Gyrase inhibitors].
    Höffler D.
    Internist (Berl); 1994 May; 35(5):484-9. PubMed ID: 8021119
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Population pharmacokinetics of marbofloxacin in horses: preliminary analysis.
    Peyrou M, Doucet MY, Vrins A, Concordet D, Schneider M, Bousquet-Mélou A.
    J Vet Pharmacol Ther; 2004 Oct; 27(5):283-8. PubMed ID: 15500564
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of gyrase inhibitors, Part 2: Renal and hepatic elimination pathways and drug interactions.
    Sörgel F, Kinzig M.
    Am J Med; 1993 Mar 22; 94(3A):56S-69S. PubMed ID: 8383921
    [Abstract] [Full Text] [Related]

  • 8. Mode of action of new quinolones: the inhibitory activity on DNA gyrase.
    Sato K, Hoshino K, Mitsuhashi S.
    Prog Drug Res; 1992 Mar 22; 38():121-32. PubMed ID: 1319080
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of gyrase inhibitors, Part 1: Basic chemistry and gastrointestinal disposition.
    Sörgel F, Kinzig M.
    Am J Med; 1993 Mar 22; 94(3A):44S-55S. PubMed ID: 8383920
    [Abstract] [Full Text] [Related]

  • 10. DNA gyrase as a drug target.
    Maxwell A.
    Trends Microbiol; 1997 Mar 22; 5(3):102-9. PubMed ID: 9080608
    [Abstract] [Full Text] [Related]

  • 11. Update on cross-resistance of fluoroquinolones.
    Garau J.
    Int J Clin Pract Suppl; 2000 Dec 22; (115):94-8. PubMed ID: 11219309
    [No Abstract] [Full Text] [Related]

  • 12. [Where are quinolones going? New agents in development].
    Holzgrabe U.
    Pharm Unserer Zeit; 2001 Dec 22; 30(5):446-8. PubMed ID: 11575182
    [No Abstract] [Full Text] [Related]

  • 13. [New quinolones, current therapies].
    Auckenthaler R.
    Schweiz Rundsch Med Prax; 1988 Nov 08; 77(45):1217-8. PubMed ID: 2847274
    [No Abstract] [Full Text] [Related]

  • 14. [Fluoroquinolones (gyrase inhibitors)].
    Senf HJ.
    Pharmazie; 1988 Jun 08; 43(6):444-7. PubMed ID: 2850589
    [No Abstract] [Full Text] [Related]

  • 15. The disposition of marbofloxacin in Eurasian buzzards (Buteo buteo) after intravenous administration.
    Garcia-Montijano M, Waxman S, Sánchez C, Quetglas J, San Andrés MI, González F, Rodríguez C.
    J Vet Pharmacol Ther; 2001 Apr 08; 24(2):155-7. PubMed ID: 11442792
    [No Abstract] [Full Text] [Related]

  • 16. The pharmacokinetic behaviour of marbofloxacin in Eurasian buzzards (Buteo buteo) after intraosseous administration.
    Garcia-Montijano M, Waxman S, Lucas JJ, Luaces I, Zalba J, González F, Andrés MI, Rodríguez C.
    Vet J; 2006 May 08; 171(3):551-5. PubMed ID: 16624724
    [Abstract] [Full Text] [Related]

  • 17. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
    Takei M, Fukuda H, Kishii R, Hosaka M.
    Antimicrob Agents Chemother; 2001 Dec 08; 45(12):3544-7. PubMed ID: 11709337
    [Abstract] [Full Text] [Related]

  • 18. On the physical interpretation of QSAR models.
    Stanton DT.
    J Chem Inf Comput Sci; 2003 Dec 08; 43(5):1423-33. PubMed ID: 14502475
    [Abstract] [Full Text] [Related]

  • 19. Framing the threat of resistance to quinolones in pharmacologic terms.
    Ambrose PG.
    Manag Care Interface; 2005 Apr 08; Suppl():4-6. PubMed ID: 15889780
    [No Abstract] [Full Text] [Related]

  • 20. Understanding topoisomerase I and II in terms of QSAR.
    Verma RP.
    Bioorg Med Chem; 2005 Feb 15; 13(4):1059-67. PubMed ID: 15670914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.